# HER2CLIMB Resistance Mechanisms The HER2CLIMB regimen combines **tucatinib**, **trastuzumab**, and **capecitabine** for HER2-positive metastatic breast cancer. When disease progresses despite this regimen, it may reflect acquired resistance, aggressive disease biology, pharmacokinetic factors, or a mixture of these. ### Why resistance may happen Cancer progression on this regimen does not always mean the same thing biologically. In some cases, the tumour finds a way around HER2 blockade. In others, the main issue may be disease burden, sanctuary-site progression, or drug-exposure variability rather than a single new mutation. ### Potential resistance mechanisms #### EGFR amplification or overexpression EGFR upregulation may allow HER2-independent signalling even when tucatinib is blocking HER2. #### Activation of downstream effectors Alterations such as **PIK3CA mutations**, **PTEN loss**, or **RAS/RAF pathway activation** can keep growth and survival signalling active despite HER2 blockade. #### HER2 truncations Truncated HER2 forms such as **p95HER2** can remove the extracellular region needed for trastuzumab binding while leaving kinase signalling active. #### Cell-cycle dysregulation Changes such as **RB1 loss** or **cyclin E amplification** may allow continued cell division even when upstream HER2 signalling is partly controlled. #### Alternative receptor tyrosine kinase upregulation Tumours may compensate through pathways such as: * **MET** * **FGFR** * **IGF1R** These can provide bypass signalling when HER2 is inhibited. #### Phenotypic transformation Some tumours may shift toward a more aggressive or less HER2-dependent state, including a more basal-like phenotype. ### Where the evidence is strongest Current evidence comes mainly from: * preclinical tucatinib-resistance models * molecular analyses of patient samples * broader HER2-targeted-resistance literature The most commonly discussed mechanisms include: * EGFR amplification * PIK3CA mutations * PTEN loss * RAS/RAF alterations * HER2 truncations * RB1 loss * cyclin E amplification * MET, FGFR, and IGF1R upregulation * phenotypic shift or loss of HER2 dependence ### Other practical reasons progression may look rapid Not all rapid progression is explained by a single molecular resistance mechanism. Other contributors may include: * high tumour burden * aggressive visceral disease * active CNS disease * pharmacokinetic variability * reduced effective drug exposure ### How this information may help This information may help support discussions about: * repeat biopsy or liquid biopsy * switching to another HER2-targeted therapy * adding pathway-directed treatment * clinical-trial eligibility * whether the pattern of progression suggests bypass signalling or phenotype change ### Questions to discuss with the care team * whether tissue or liquid-biopsy testing is appropriate * whether any actionable alterations may change treatment options * whether the current progression pattern suggests a known resistance route * whether clinical trials or alternative HER2-targeted strategies are available ### Related pages * [HER2CLIMB Guide](/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/her2climb-guide.md) * [Liquid Biopsies for HER2-Positive Resistance](https://app.gitbook.com/o/wnb0zPTNLnW6SRJfVBZV/s/Iyy2bZWxLPaSj5B4dS3v/~/edit/~/changes/1/breast-cancer/her2-positive/her2climb/liquid-biopsy-for-her2-positive-resistance/~/agent) * [Natural Compounds and CYP3A4 — HER2CLIMB Considerations](/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/natural-compounds-and-cyp3a4-her2climb-considerations.md) ### References Abstract PD8-06: Acquired resistance to tucatinib\ Treating advanced breast cancer: a spotlight on tucatinib\ Potential Resistance Mechanism to Tucatinib in HER2+ Breast Cancer\

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

{% hint style="warning" %} This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use. {% endhint %} {% hint style="info" %} © 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text. {% endhint %} --- # Agent Instructions: Querying This Documentation If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question. Perform an HTTP GET request on the current page URL with the `ask` query parameter: ``` GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/breast-cancer/her2-positive/her2climb/her2climb-resistance-mechanisms.md?ask= ``` The question should be specific, self-contained, and written in natural language. The response will contain a direct answer to the question and relevant excerpts and sources from the documentation. Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.